American gene therapy company MeiraGTx (MGTX.US) announced that it has reached a potential licensing agreement worth over $475 million with Eli Lilly (LLY.US), granting Eli Lilly rights to an experimental gene therapy for the treatment of rare hereditary blindness diseases.
Under the agreement, MeiraGTx will receive a $75 million upfront payment and has the opportunity to earn over $400 million in milestone payments. Additionally, the company is eligible to receive tiered royalties on the licensed product

MGTX

Eli Lilly has reached a licensing agreement with MeiraGTx worth over $475 million to obtain the rights to a gene therapy for the treatment of rare hereditary blindness diseases. MeiraGTx will receive a $75 million upfront payment and has the opportunity to earn over $400 million in milestone payments, as well as being eligible for tiered royalties

礼来斥近 5 亿美元获 MeiraGTx 先天失明基因治疗药权利